UroGen Pharma Ltd (NASDAQ:URGN) price on Thursday, March 28, rose 0.27% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $15.00.
A look at the stock’s price movement, the close in the last trading session was $14.96. The beta value (5-Year monthly) was 1.10. Turning to its 52-week performance, $24.13 and $7.79 were the 52-week high and 52-week low respectively. Overall, URGN moved -17.45% over the past month.
UroGen Pharma Ltd’s market cap currently stands at around $511.80 million, with investors looking forward to this quarter’s earnings report slated for May 09, 2024 – May 13, 2024. Analysts project the company’s earnings per share (EPS) to be -$0.87, which has seen fiscal year 2024 EPS growth forecast to increase to -$3.65 and about -$2.39 for fiscal year 2025. Per the data, EPS growth is expected to be -2.80% for 2024 and 34.50% for the next financial year.
Analysts have a consensus estimate of $21.39 million for the company’s revenue for the quarter, with a low and high estimate of $20 million and $22.82 million respectively. The average forecast suggests up to a 24.50% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2024 to grow to $99.3 million, representing a 20.10% jump on that reported in the last financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was 1 upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that URGN is a Hold. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
URGN’s current price about -8.97% and -10.52% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 41.23, while 7-day volatility ratio is 9.85% and 7.42% in the 30-day chart. Further, UroGen Pharma Ltd (URGN) has a beta value of 1.07, and an average true range (ATR) of 1.18.
If we refocus on UroGen Pharma Ltd (NASDAQ:URGN), historical trading data shows that trading volumes averaged 0.55 million over the past 10 days and 349.40K over the past 3 months. The company’s latest data on shares outstanding shows there are 32.49 million shares.
The 17.38% of UroGen Pharma Ltd’s shares are in the hands of company insiders while institutional holders own 72.01% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 4.25 million on Mar 15, 2024, giving us a short ratio of 12.84. The data shows that as of Mar 15, 2024 short interest in UroGen Pharma Ltd (URGN) stood at 12.46% of shares outstanding, with shares short rising to 4.01 million registered in Feb 15, 2024. Current price change has pushed the stock 0.00% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the URGN stock continues to rise going into the next quarter.
